Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
Journal: Annals of the rheumatic diseases
Published: April 24, 2025
Criteria for defining and dating onset of organ system involvement in systemic sclerosis.
Journal: Journal of scleroderma and related disorders
Published: April 17, 2025
'Am I doing this right?' Physician perceptions of the global assessment in clinical trials of systemic sclerosis.
Journal: Rheumatology (Oxford, England)
Published: April 10, 2025
Cognitive debriefing of the Scleroderma Health Assessment Questionnaire in diffuse cutaneous systemic sclerosis.
Journal: Journal of scleroderma and related disorders
Published: March 09, 2025
A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
Journal: Rheumatology (Oxford, England)
Published: May 24, 2022
Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 12, 2021
Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis.
Journal: Annals of the rheumatic diseases
Published: June 22, 2021
Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance.
Journal: American journal of respiratory and critical care medicine
Published: June 09, 2021
Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial.
Journal: American journal of respiratory and critical care medicine
Published: March 02, 2021
Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
Journal: Rheumatology (Oxford, England)
Published: September 23, 2020
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 25, 2019
Last Updated: 09/26/2026